News

Reviews Pipeline Therapeutics for Retinoic Acid Receptor Gamma by Companies and Universities/Research institutes with the help of latest report

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) – Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.

Report Source: https://www.themarketreports.com/report/retinoic-acid-receptor-gamma-rar-gamma-or-nuclear-receptor-subfamily-1-group-b-member-3-or-nr1b3-or-rarg-pipeline-review-h1

The report ‘Retinoic Acid Receptor Gamma – Pipeline Review, H1 2019’ outlays comprehensive information on the Retinoic Acid Receptor Gamma targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Purchase this report at: https://www.themarketreports.com/report/buy-now/1488138

Scope

  • The report reviews Retinoic Acid Receptor Gamma targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Retinoic Acid Receptor Gamma targeted therapeutics and enlists all their major and minor projects
  • The report assesses Retinoic Acid Receptor Gamma targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Retinoic Acid Receptor Gamma targeted therapeutics

Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/1488138